Gravitate Health FHIR Implementation Guide (FHIR R4)
0.1.0 - CI Build

Gravitate Health FHIR Implementation Guide (FHIR R4), published by . This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health-ips/ and changes regularly. See the Directory of published versions

## Example Bundle: IPS Example 4

id: gravitate-ips-4
Composition status: final
Composition Type: Patient summary Document
Subject:
identifier: ips-4
Name: IPS 4 example Gravitate
active: true
gender: female
Birth Date: 1989-05-05

### Sections

#### Allergies and Intolerances

Allergy: Pollen (256259004)
clinicalStatus: active
verificationStatus: confirmed
Reaction: Allergic rhinitis caused by pollen (21719001)
Allergy: Intolerance to lactose (782415009)
clinicalStatus: active
verificationStatus: confirmed
Reaction: Abdominal pain (21522001)

#### Problem List

Condition: Psoriasis (9014002)
clinicalStatus: active
asserter: Dr. Anna Karlsson
Condition: Congestive heart failure (42343007)
clinicalStatus: active
asserter: Dr. Anna Karlsson
onsetDateTime: 2015
Condition: Hypertension (38341003)
clinicalStatus: active
onsetDateTime: 1993

#### Medication Summary

Medication: Remsima 100 mg powder for concentrate for solution for infusion
status: active
Medication Detail:

- System https://spor.ema.europa.eu/pmswi Code: EU/1/13/853/001 [Remsima 100 mg powder for concentrate for solution for infusion]

- System https://www.who-umc.org/phpid Code: 0xF79CABF272B6A7EEF104DDDA44E82718 [Infliximab 100 mg powder for concentrate for solution for infusion]

Dose Form: Powder for concentrate for solution for injection/infusion
Ingredient: INFLIXIMAB (http://fdasis.nlm.nih.gov#B72HH48FLU)
strength: 100 mg/1 Vial
Route: Intravenous use
Medication: Karvea 75 mg Tablet
status: active
Medication Detail:

- System https://spor.ema.europa.eu/pmswi Code: EU/1/97/049/001 [Karvea 75 mg/ 1 tablet, Tablet]

- System https://www.who-umc.org/phpid Code: 0xF79CABF272B6A7EEF104DDDA44E82719 [Irbesartan, 75 mg/ 1 tablet, Tablet]

- System http://www.whocc.no/atc Code: C09DA04 [irbesartan and diuretics]

Dose Form: Tablet
Ingredient: irbesartan (http://fdasis.nlm.nih.gov#J0E2756Z7N)
strength: 75 mg/1 Tablet
Route: Oral use
Medication: Humalog 100 U/ml 5 pre-filled pen
status: active
Medication Detail:

- System https://spor.ema.europa.eu/pmswi Code: EU/1/96/007/035 [Humalog Mix50 KwikPen 100 U/ml 5 pre-filled pen]

- System https://www.who-umc.org/phpid Code: 0xF79CABF272B6A7EEF104DDDA44E82717 [Insulin Lispro 100 U/ml 5 pre-filled pen]

Dose Form: Suspension for injection
Ingredient: Insulin Lispro (http://fdasis.nlm.nih.gov#GFX7QIS1II)
strength: 100 U/1 ml
Route: Subcutaneous use
Medication: citalopram
status: active
Medication Detail:

- System https://spor.ema.europa.eu/pmswi Code: 204447 [Citalopram Aurovitas 10 mg tablet]

Route: Subcutaneous use
Medication: Amlodipine Italy
status: active
Medication Detail:

- System https://spor.ema.europa.eu/pmswi Code: AMLODIPINA-DOC-GENERICI-tablet-10mg--71-ITA-MPD [AMLODIPINA DOC GENERICI compresse 10 mg]

Route: Oral use
Medication: Amlodipine Norway
status: active
Medication Detail:

- System https://spor.ema.europa.eu/pmswi Code: AMLODIPINA-SANDOZ-tablet-10mg--3-NO-MPD [Amlodipin sandoz 10 mg TABLETTER]

Route: Oral use

#### Vital Signs

#### Results

#### Pregnancy History

#### Social History